Boehringer Ingelheim: External Collaborative Research (ECR) Grant

Boehringer Ingelheim: External Collaborative Research (ECR) Grant

Status: ACTIVE
Funder: Boehringer Ingelheim Pharmaceuticals, Inc.
Last Updated: October 14, 2025

Summary

The External Collaborative Research (ECR) program by Boehringer Ingelheim invites academic and community scientists to propose collaborative studies aimed at protocol development and result publication. This program offers potential drug and financial support, excluding direct salary for the Principal Investigator. Budgets must represent fair market value and will be negotiated further. Research interests span therapeutic areas including Cardio-Renal-Metabolic, Mental Health, Dermatology, and Oncology, encouraging innovative solutions to unmet medical needs.

Overview

External Collaborative Research (ECR) The External Collaborative Research (ECR) program is open to all qualified academic and community-based scientists or consortia that are interested in proposing a study and wish to collaborate with Boehringer Ingelheim to develop a protocol and analyze and publish the results. In addition to providing intellectual contributions, Boehringer Ingelheim may provide drug and/or financial support for an ECR. Boehringer Ingelheim does not serve as the Regulatory Sponsor for an ECR. The preliminary budget for ECRs should reflect fair market value for all costs and cannot include direct salary support for the Principal Investigator. Budgets for ECRs will be further negotiated pending finalization of the collaborative protocol. While the research interests listed within the therapeutic areas are of focus to Boehringer Ingelheim, other research interests may be considered. Cardio-Renal-Metabolic:Explore the effects of empagliflozin on diseases of the cardio-renal-metabolic systems in patients in under-represented populations Understand the extent of real-world implementation of guideline-based management of patients and/or solutions to overcome barriers of GDMT implementationExamine the role of empagliflozin in transition-of-care models to outpatient setting in patients with cardio-renal[1]metabolism diseases Examine the role of empagliflozin in collaborative care models of disease of the cardio-renal-metabolic systemsEstablishing sequential and interconnected disease pathway to support the impact of early treatment on CRM pathway Understand the duration of GDMT for CRM conditions and factors associated with treatment discontinuation & re-initiationMental Health:Schizophrenia:Evaluate patient assessment, symptom evaluation, and diagnosis patterns for negative symptomsEvaluate patient assessment, symptom evaluation, and diagnosis patterns for cognitive symptomsAssess the treatment landscape and trajectory of disease progression for cognitive and negative symptomsPost-Traumatic Stress Disorder:Evaluate patient assessment, symptom evaluation, and diagnosis patternsAssess the treatment landscape and trajectory of disease progressionEvaluate disease progression with respect to index eventDigital Therapeutics:Increase the clinician's awareness of the current unmet medical needs and burden of disease in patients with schizophrenia, including cognitive and negative symptoms associated with schizophrenia as well as the potential utility of digital therapeutics in psychiatry, including schizophrenia.Improve the clinician's understanding of the management and limitations of treating cognitive and negative symptoms of schizophrenia, as well as ongoing developments in clinical research in schizophrenia and digital therapeutics in psychiatry.Major Depressive Disorder:Evaluate patient assessment, symptom evaluation, and diagnosis patternsAssess the treatment landscape and trajectory of disease progressionDermatology:Studies investigating the natural course of the disease in patients with GPP (including risk factors; predictors, triggers, frequency and impact of flares; symptoms between flares; systemic symptoms; mortality) Studies investigating frequency and impact of extracutaneous manifestations and comorbidities (Anxiety/Depression, Cardiovascular Disease) in patients with GPP Studies to support the development, evaluation and/or validation of tools that assess patient-reported outcomes in patients with GPP Studies investigating the limitations (residual symptoms, incomplete/delayed flare resolution etc) of therapies based on other MOAs used to treat GPP Studies investigating pathogenesis of GPP Studies investigating incidence and/or prevalence of GPP Studies investigating management of patients with GPP, including treatment patterns, supportive and/or interventions to support/increase adherence to treatments (e.g., home programs, nurse support, other innovative digital tools)Oncology:Soft Tissue Sarcoma:Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomesMonotherapy or combination therapy (including novel treatment combinations or radiotherapy) in MDM2 amplified or overexpressed tumors (p53 wild type)Biliary Tract Cancer:Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomesCombination therapy (including novel treatment combinations) in MDM2 amplified or overexpressed tumors (p53 wild type)Non-Small Cell Lung Cancer:Real World Data: The natural history, development and progression of the disease, molecular testing and pathological subtyping, diagnostic/treatment landscape and efficacy/safety outcomesMonotherapy or combination therapy (including novel treatment combinations) in NSCLC with a documented HER2 aberration: TKD and non-TKD mutation positive OR overexpression OR gene amplification OR gene rearrangement involving HER2Respiratory:Fibrosing ILDStudies investigating newer tools for ILD screening, earlier diagnosis, or disease assessmentStudies investigating the natural course of the disease in patients (pediatric and adult) with ILDs (including risk factors and predictors of disease progression)Studies investigating management of ILDs (in pediatric and adult patients) including: Diagnosing and managing co-morbiditiesDiagnosing and managing acute exacerbationsEvaluating and managing extra-pulmonary manifestations of patients (pediatric and adult) with autoimmune-ILDsNon-pharmacologic management, including supportive and palliative care, home monitoring programs, nurse support, rehabilitation, physical training, oxygen use, and other innovative digital toolsMetabolic-MASH/MASLD:Understand the gaps in the progression and clinical management of MASH and advanced liver disease Metabolic-Obestiy:Funding Only (non-drug) requestsUnderstanding the physical and psychological burden of disease for patients living with ObesityUnderstanding weight stigma and obesity bias and its impact on the clinical management of Obesity Understanding QOL data available and additional opportunities to characterize positive impact of pharmacologic treatments (non-scale victories)Understanding physicians’ recognition in the difference in morbidity and mortality between patients with high waist to hip ratio (visceral fat) vs. other distribution (use of clinical tools/measurement in current practice, evaluation of current practices)Understanding patient factors in patient’s acceptance of treatment and factors encouraging/supporting adherence (to treatment and management)

Eligibility

You can learn more about this opportunity by visiting the funder's website. In general, grant funding to support clinical (interventional and non-interventional) and health outcomes research studies are all acceptable proposals. If you have an idea that could potentially advance medical knowledge or improve patients’ lives, learn more about the grants and funding Boehringer Ingelheim may provide. Examples of who may apply (based in the US):Scientists Healthcare Providers Researchers Medical Education Communication Companies Medical Professional Organizations Healthcare / Academic Institutions

Ineligibility

Proposals in the following areas are not being considered:Biosimilars, Fibrosing ILDs